Navigation Links
Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

for the Osteoporosis Therapeutics Market 51

4.17.2 Barriers for the Postmenopausal Osteoporosis Therapeutics Market 52

4.18 Opportunity and Unmet Need 54

4.19 Key Takeaway 57

5 Osteoporosis Therapeutics: Competitive Assessment 58

5.1 Overview 58

5.2 Strategic Competitor Assessment 58

5.3 Product Profile for the Major Marketed Products in the Osteoporosis Therapeutics Market 60

5.3.1 Fosamax (alendronate sodium) 60

5.3.2 Actonel (risedronate sodium) 62

5.3.3 Boniva (ibandronate sodium) 64

5.3.4 Reclast (zoledronic acid) 66

5.3.5 Evista (raloxifene hydrochloride) 68

5.3.6 Prolia (denosumab) 70

5.3.7 Forteo (teriparatide [rDNA origin]) injection 71

5.3.8 Miacalcin (salmon calcitonin) 74

5.3.9 Activella (estradiol, norethindrone acetate) 75

5.3.10 Premarin (estrogen) 76

5.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate) 77

5.4 Key Takeaway 78

6 Osteoporosis Therapeutics: Pipeline Assessment 79

6.1 Overview 79

6.2 Strategic Pipeline Assessment 79

6.3 Osteoporosis Therapeutics – Pipeline Analysis by Clinical Phase of Development 79

6.3.1 Osteoporosis Therapeutics – Phase III and Regulatory Filed Clinical Pipeline 80

6.3.2 Osteoporosis Therapeutics – Phase II Clinical Pipeline 81

6.3.3 Osteoporosis Therapeutics – Phase I Pipeline 82

6.3.4 Osteoporosis Therapeutics –Pre-clinical and Discovery Phase Pipeline 83

6.4 Osteoporosis Therapeutics – Pipeline by Mechanism of Action 84

6.5 Technology Trends Analytical Framework 85

6.6 Osteoporosis Therapeutics – Most Promising Drugs in Clinical Development 87

6.7 Most Promising Drugs in Clinical Development 88

6.7.1 Viviant 88

6.7.2 Fablyn 89

6.7.3 Aprela 90

6.7.4 EX101 91

6.7.5 Odanacatib (MK-0822) 92

6.7.6 NB S101 93
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
2. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
3. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
4. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
5. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
6. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
7. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
8. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
9. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease
10. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
11. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... bloggers and influencers across North America ... that melanoma prevention begins with parents-encouraging everyone to create a ... Duff , and parenting author Alyson Schafer are ... Monday to share this poignant video message: Click ... Cornfield Melanoma Fund (DCMF)-producers of the viral video ...
(Date:5/6/2015)... , May 06, 2015 Research and ... the addition of the "Cannulas Market by ... Injector, Infusion, Venous, Microcannula), Material (Plastic, Metal) & ... Forecast to 2020" report to their offering. ... to grow at a CAGR of 5.6% from ...
(Date:5/6/2015)... Maine , May 6, 2015  Membership in ... according to a Healthcare Business Strategy report released ... also known as Medigap or Med Supp plans, ... 31, 2014, a 5.2% increase from 2013. Between ... increased by 551,135 covered lives.  Though UnitedHealth was ...
Breaking Medicine Technology:Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announced ... Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran ... was presented at the,American College of Gastroenterology (ACG) ... provided data from a preclinical study of,RDEA119, the ...
... ,Sosei Group Corporation ("Sosei"; TSE Mothers Index: ... announce results of two Phase II studies,evaluating ... presented at the,annual congress of the European ... data show that NVA237 (glycopyrronium bromide), a ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
(Date:5/6/2015)... MA (PRWEB) May 06, 2015 ... for healthcare professionals and students, announced today that in ... 94% confirmed that use of the clinical decision support ... by the end of 2014, UpToDate users in more ... clinical topics per month, on average. In Germany alone, ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... In March, Dr. Rami K. Batniji ... Masterclass. As Europe’s most exclusive rhinoplasty conference, the attendees ... Dr. Batniji was hand chosen to speak by the President ... Dr. Pietro Palma. , The Milano Masterclass is ... hosts a diverse, multi-national faculty; each considered a rhinoplasty expert ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and ... week as having one the best Extra Virgin Olive Oils ... Peloponnese region of Greece and known as Laconiko , ... of Medium Olive Oil, which is defined by the competition ... over 700 producer applicants from 25 different countries applying, Laconiko ...
(Date:5/6/2015)... The Alliance for Regenerative Medicine ... and advanced therapies community, today announced the release ... in-depth look at sector trends and metrics from ... report is available online here and ... available here . , Using information provided ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... labels to help cut heart disease, according to researchers from ... their arguments in this week's British Medical Journal, say that ... number one killer, estimated to be responsible for almost 50 ... cardiovascular disease is reported to cost the EU economy an ...
... because a staff nurse has refused to send an ambulance to ... had an agonizing pain in her lower abdomen. Hence she called ... could not have an ambulance and had to wait for another ... the GP arrived he just gave her some painkillers. ...
... 35-year-old woman in Madhya Pradesh survived carrying a dead foetus ... Friday at the government hospital at Khargone, 348 km from ... removed from her womb. ,Renubai conceived two years ... the seventh month of her pregnancy, her family members thought ...
... it has received the tentative new drug approval ... anti-HIV treatment. // ,The fixed drug ... Abacavir 300mg Tablets, the company informed the Bombay ... is cost-effective and reduces the threat of resistance ...
... of a bird flu vaccine against the deadly H5N1 variety ... unvaccinated monkeys, by researchers at two universities.// ,According ... University, the results are expected to be known within about ... shed light on numerous aspects of the strain's infection mechanism ...
... Act, celebrating its third anniversary, has reduced secondhand smoke ... a study conducted by RTI International. ,According to ... of Health’s Tobacco Control Program, exposure to secondhand smoke ... in the year following the implementation of the law. ...
Cached Medicine News:Health News:Scientists Push for Labeling of all Fats to Avoid Heart Disease 2Health News:New York’s Secondhand Smoke Exposure Continues to Declin 2
... combining the corrosion resistance of stainless ... of copper, SANYO offers an electro-polished ... and maintenance-free. The sterile environment promotes ... results and the safety of laboratory ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... highly accurate portable, waterproof system for pH, mV ... pH results can be obtained when used with ... • This GLP/GMP compliant system includes an RS-232 ... computer. Up to 100 data sets can be ...
Medicine Products: